摘要
社会文化的进步和公共卫生事业的发展带来人均寿命的延长,冠心病是老年人的常见病和致死原因之一。由于临床试验常将80岁及以上的高龄患者排除在外,导致随机对照试验研究数据仍相对较少,研究表明,很多已经得到循证医学反复验证的治疗方式在高龄患者中的临床应用十分有限。
出处
《老年医学与保健》
CAS
2015年第3期191-193,共3页
Geriatrics & Health Care
参考文献22
-
1Brenes-Salazar JA, Forman DE. Advances in percutaneous cor- onary interventions for elderly patients [J]. Progress in Cardio- vascular Diseases, 2014,57 (2): 176-186.
-
2Bauer T, Mollmann H, Weidinger F, et al. Predictors of hospital mortality m the elderly undergoing percutaneous coron- ary intervention for acute coronary syndromes and stable angina [J]. International Journal of Cardiology, 2011,151 (2): 164 -169.
-
3Antman EM, Anbe DT, Armstrong PW, eta1. 2004ACC/AHA guidelines for the management of patients with ST-elevation my- ocardial infarction executive summary. A report of the American college of cardiology/American heart association task force on- practice guidelines (Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction) [J]. Criculation, 2004,110 (9): e82-292.
-
4Karha J, Topoi EJ. Primary percutaneous coronary intervention vs. fibrinolytic therapy for acute ST-elevation, yocardial m- fraction in the elderly [J]. Am J Geriatr Cardiol, 2006,15: 19-21.
-
5Stenestrand. Ulf, Lars W. Fibrinolytic therapy in patients 75 years and older with ST-segment elevation myocardial infarction [J]. Arch lnternMed, 2003,163 (8): 965-971.
-
6Mehta RH, Granger CB, et al. Reperfusion strategies for acute myocardial infarction in the elderly: Benefits and Risks [J]. American College of Cardiology, 2005,45 (4): 471-478.
-
7Ayanian JZ, Braunwald E. Thrombolytic therapy for patients with myocardial in farction who are older than 75 years: do the risks outweigh the benefits [J]. Circulation, 2000,101:2224-2226.
-
8Fibrinolytic therapy trialists' (FTT) Collaborative Group. Indi- cations for fibrinolytic therapy in suspected acute myocardial in- farction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients [J]. Lancet, 1994,343 : 311-322.
-
9Bueno H, Betriu A, Heras M, et al. Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN An- cianos) randomized trial and pooled analysis with previous stu- dies. [J]. European Heart Journal, 2011,32 : 51-60.
-
10无.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2010,38(8):675-690. 被引量:1985
二级参考文献33
-
1Collaborative Research Group of Reperfusion Therapy in Acute Myocardial Infarction.重组葡激酶与重组组织型纤溶酶原激活剂治疗急性心肌梗死的随机多中心临床试验[J].中华心血管病杂志,2007,35(8):691-696. 被引量:43
-
2Harris MI. Diabetes in America: epidemiology and scope of the problem. Diabetes Care 1998; 21(Suppl 3): C11-C14.
-
3Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035-2038.
-
4Brooks MM, Jones RH, Bach RG, et al. Predictors of mortal- ity and mortality from cardiac causes in the bypass angio- plasty revascularization investigation (BARI) randomized trial and registry. For the BARI Investigators. Circulation 2000; 101: 2682-2689.
-
5Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Com- parative effectiveness of revascularization strategies. N Engl J Med2012; 366:1467 1476.
-
6Nicholls S J, Tuzcu EM, Kalidindi S, et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remod- eling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardio12008; 52: 255-262.
-
7Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revasculariza- tion Investigation (BARI). Circulation 1997; 96:1761-1769.
-
8King SB III, Kosinski AS, Guyton RA, et al. Eight-year mor- tality in the Emory Angioplasty versus Surgery Trial (EAST). JAm Coll Cardio12000; 35:1116 -1121.
-
9Serruys PW, Ong AT, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arte- rial Revascularization Therapies Study (ARTS) randomized trial. JAm Coll Cardio12005; 46:575-5 81.
-
10Rodriguez AE, Baldi J, Fem~dez Pereira C, et al. Five-year follow-up of the Argentine randomized trial of coronary an- gioplasty with stenting versus coronary bypass surgery in pa- tients with multiple vessel disease (ERACI II). J Am Coll Cardio12005; 46:582 588.
共引文献2008
-
1毕颖斐,王贤良,赵志强,侯雅竹,毛静远,张伯礼.冠心病中医证候地域性特征的临床流行病学调查[J].中医杂志,2020,61(5):418-422. 被引量:65
-
2崔茵茵,吕欢,刘思蕾.血清淀粉样蛋白A及基质金属蛋白酶-9水平对ST段抬高型心肌梗死患者介入治疗后心力衰竭发生的影响[J].慢性病学杂志,2024(3):471-473.
-
3朱战辉.注射用重组人尿激酶原冠状动脉内注射+经皮冠状动脉介入治疗术在血栓高负荷病变急性ST段抬高心肌梗死患者中的应用效果[J].慢性病学杂志,2023(6):951-953.
-
4林建粦.血清25羟维生素D3、脑钠肽、C反应蛋白与老年急性心肌梗死患者发生恶性室性心律失常的关系[J].慢性病学杂志,2022(9):1364-1368. 被引量:1
-
5何金易,丁荣晶,夏昆,王历,胜利,胡大一.广泛性焦虑问卷与医院焦虑量表在急性冠脉综合征患者中焦虑筛查的应用价值[J].慢性病学杂志,2022(5):797-800. 被引量:1
-
6孙爱民.血塞通对急性ST段抬高型心肌梗死患者PCI术后炎症因子及心功能的影响[J].慢性病学杂志,2021(9):1425-1427. 被引量:1
-
7汪沛澍.替罗非班在STEMI患者PCI术中应用的疗效及安全性研究[J].心血管病防治知识(学术版),2020(28):24-26.
-
8季会娟.对比替格瑞洛和氯吡格雷在急性心肌梗死病人溶栓后PCI治疗中的应用效果[J].新疆医学,2023,53(5):558-560. 被引量:4
-
9牛敬.格林模式在急性心肌梗死患者PCI术后康复训练管理中的应用价值[J].实用心脑肺血管病杂志,2020,28(S01):156-158. 被引量:3
-
10仇杰,谢勇,李雨涵,徐超凡.入院时胸导联Q波总振幅与R波总振幅比值对急性ST段抬高型前壁心肌梗死患者急诊经皮冠状动脉介入治疗后短期预后的预测价值研究[J].实用心脑肺血管病杂志,2020,0(1):17-22. 被引量:9
同被引文献40
-
1杨捷.凯时(前列地尔)注射液治疗慢性心力衰竭的临床疗效及安全性观察[J].中外医疗,2007,26(23):3-4. 被引量:12
-
2杨薪,刘映峰,王世祥,陈安,汪新良.前列地尔对慢性心衰大鼠心肌基质金属蛋白酶表达及纤维化的影响[J].中国动脉硬化杂志,2015,23(3):266-270. 被引量:13
-
3何正富,郦志军.前列腺素E1在心内直视术中对再灌注心肌的影响[J].浙江大学学报(医学版),2004,33(4):353-356. 被引量:4
-
4蒋永芳,许允,张永红,龚国忠.前列地尔对慢性重型乙肝患者血清肿瘤坏死因子-α的影响[J].中国新药杂志,2005,14(8):1057-1058. 被引量:21
-
5冯国清,韩联合,程红梅,付润芳,戚敏.前列地尔对大鼠主动脉球囊损伤后内皮素、炎性细胞因子的影响[J].中国新药与临床杂志,2005,24(9):719-722. 被引量:8
-
6彭婕.34例前列地尔所致不良反应分析[J].中国新药杂志,2006,15(1):65-67. 被引量:14
-
7曹国良,乔永芳,刘新兵,俞建华.辛伐他汀早期干预对非ST抬高型急性冠脉综合征细胞因子水平的影响[J].实用诊断与治疗杂志,2006,20(7):478-480. 被引量:40
-
8李勇,唐捷.前列地尔的药理研究进展[J].西南军医,2006,8(6):79-81. 被引量:70
-
9贾因棠,王守义,解中坚.前列腺素E_1对肿瘤坏死因子水平及磷脂酶A_2活性的影响[J].中国病理生理杂志,1997,13(6):722-724. 被引量:5
-
10王勇.前列地尔对冠心病心力衰竭患者心功能及内皮细胞功能的影响[J].山东医药,2009,49(33):63-64. 被引量:20
引证文献3
-
1蒋庆渊,陆铭,李锦玉,李志强,刘春兰,刘莹莹.阿托伐他汀对急性心肌梗死患者血清C-反应蛋白和白细胞介素-1的影响及临床意义[J].老年医学与保健,2017,23(3):181-182. 被引量:4
-
2马潇泓,容耀聪,赫明萍.前列地尔在冠状动脉粥样硬化性心脏病治疗中的应用[J].老年医学与保健,2017,23(5):444-446. 被引量:5
-
3江涛,廖英坚.前列地尔治疗冠状动脉粥样硬化性心脏病患者的临床效果[J].中国当代医药,2020,27(6):76-78. 被引量:1
二级引证文献10
-
1邓淑妍,刘婉珊,梁毅.不同剂量他汀类药物对急性心肌梗死早期治疗效果的影响分析[J].智慧健康,2021,7(29):151-153.
-
2曹向宁.前列地尔对老年脑血栓VBI的血液流变学指标、颈动脉斑块及动脉硬化指数的影响[J].广西医科大学学报,2019,36(8):1300-1305. 被引量:6
-
3刘晓建,刘云江.不同剂量瑞舒伐他汀治疗急性心肌梗死的临床效果观察[J].中国处方药,2020,18(2):68-69. 被引量:2
-
4丁楠.通心络胶囊联合阿托伐他汀对急性心肌梗死患者炎性因子及心功能的影响[J].包头医学,2020,44(1):44-46. 被引量:4
-
5江涛,廖英坚.前列地尔治疗冠状动脉粥样硬化性心脏病患者的临床效果[J].中国当代医药,2020,27(6):76-78. 被引量:1
-
6唐丹丹,黄远东.前列地尔注射液对成人急性呼吸窘迫综合征患者呼吸功能和微循环的影响[J].中国医学前沿杂志(电子版),2020,12(4):30-34. 被引量:1
-
7褚毅,张景,代月.前列地尔联合常规疗法对缺血性肠病患者血清IFABP和D-dimer水平的影响观察[J].当代医学,2020,26(18):31-33. 被引量:2
-
8于红波,刘亚群,尹栋.慢性心力衰竭患者血清正五聚蛋白3、成纤维细胞生长因子2的表达水平及其与心肌重构和心功能的相关性[J].中国医药导报,2021,18(23):68-71. 被引量:9
-
9李克刚,祁正军.急性心肌梗死PCI术前服用不同剂量阿托伐他汀对血浆脑钠肽及左心室重构的影响[J].临床合理用药杂志,2021,14(29):4-6. 被引量:1
-
10罗瑞星.前列地尔干乳剂联合阿司匹林、氯吡格雷对非ST段抬高急性心肌梗死患者心功能及血清BNP水平的影响[J].现代诊断与治疗,2018,29(24):3986-3988. 被引量:1
-
1丁荣晶.西尼地平临床应用中国专家共识[J].中华高血压杂志,2012,20(9):823-826. 被引量:2
-
2张琦.517例胃镜检查患者的舒适护理[J].中国城乡企业卫生,2013,28(5):82-83.
-
3郑合明,王羽,李小烽,王传钢,柯庚富,于红阳,罗君,杜正旺,张根红,许来平,王效文,赵玉丑.碘缺乏病防治对社会文化促进作用的研究[J].中国地方病防治,1995,10(3):159-161.
-
4刁孟元,黄凤楼.以循证医学为指导加强疗养院代谢综合征患者的健康管理[J].中国疗养医学,2010,19(1):15-16.
-
5朱高华,邢洪敏.健康教育在“非典”预防控制中的作用[J].中国健康教育,2004,20(4):328-328.
-
6陈志坚,廖玉华.心室颤动治疗策略的思考[J].临床心血管病杂志,2007,23(8):561-562. 被引量:2
-
7初磊,李怀芳.管理好我们的心脏--心跳,生命的节律[J].家庭用药,2011(10):11-12.
-
8秦晴,钱菊英.老年人冠心病经皮冠状动脉介入治疗相关问题与展望[J].老年医学与保健,2014,20(1):6-9.
-
9李玉珍,徐晓琴.56例高血压病的治疗与护理[J].家庭护士(专业版),2008,6(14):1279-1279.
-
10获得性免疫缺陷综合征(AIDS艾滋病)[J].国外科技资料目录(医药卫生),1997(11):37-37.